Amdizalisib is a small molecule commercialized by Hutchmed China, with a leading Phase I program in Nodal Marginal Zone B-Cell Lymphoma. According to Globaldata, it is involved in 12 clinical trials, of which 6 were completed, 3 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Amdizalisib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Amdizalisib is expected to reach an annual total of $24 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Amdizalisib Overview

Amdizalisib (HMPL-689) is under development for the treatment of hematological B cell malignancies including chronic lymphocytic leukemia (CLL), indolent non-hodgkin lymphoma, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), Waldenstrom macroglobulinemia (WM), peripheral T-cell lymphomas (PTCL) and mantle cell lymphoma (MCL). It is administered orally. The drug candidate is a small molecule that targets PI3K Delta. HMPL-689 was also under development for the treatment of  hematological malignancies  diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma. The drug candidate is a new molecular entity (NME).

It was under development for the treatment of indolent non-hodgkin lymphoma.

Hutchmed China Overview

Hutchmed China (Hutchmed) formerly known as Hutchison China MediTech is a biopharmaceutical company that discovers, develops, manufactures, and commercializes drugs for the treatment of solid tumors and hematological malignancies, and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe, and Australia. The company offers prescription drugs to hospitals in China through a direct sales force. It distributes consumer health products in China. Hutchmed is headquartered in Kowloon, Hong Kong.

For a complete picture of Amdizalisib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.